SOURCE-LINKED STUDY SUMMARY
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Abstract summarizedQuality not appraised
- What was studied
- Phase 2 randomized trial comparing three tirzepatide doses with placebo for metabolic fatty liver inflammation and scarring.
- Who / model studied
- 190 participants with biopsy-confirmed liver inflammation and moderate or severe fibrosis, studied for 52 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary outcome, inflammation resolution without worse scarring, occurred in 44%, 56% and 62% across increasing tirzepatide doses, versus 10%. The key secondary outcome, improved scarring without worse inflammation, occurred in 55%, 51% and 51%, versus 30%. Digestive adverse events were most common and usually mild or moderate.
- Limitations & context
- Only 157 participants had evaluable follow-up biopsies. Missing results were estimated assuming the pattern seen with placebo.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2401943